GOBiolab Decides to Register US Patent for Liver Damage Treatment Material

Plans to Accelerate Entry into the MASLD Market
Through Acquisition of Global Rights

GOBIO LAB, a company specializing in microbiome drug development, announced on the 8th that it has been granted a U.S. patent for its human microbiome-derived liver injury treatment material used in its metabolic dysfunction-associated steatotic liver disease (MASLD) therapy.

GobioLab

MASLD refers to liver diseases related to metabolic dysfunction, ranging from simple steatosis to progressive fibrosis and cirrhosis. MASLD shows a pattern of increasing prevalence parallel to obesity and metabolic syndrome patients, and its prevalence is rising globally.

GOBIO LAB utilized its proprietary functional strains of the genus Ruminococcus spp. to confirm the liver injury improvement effects in patients with insulin resistance. In particular, these functional strains demonstrated excellent effects in reducing blood ALT/AST levels, fibrosis gene expression, and liver-to-body weight ratio, while significantly increasing secondary bile acid concentrations in the cecum.

GOBIO LAB’s MASLD treatment, based on human-derived strains, greatly reduces side effects. Additionally, it can be developed into an oral formulation, offering the advantage of easy administration.

A GOBIO LAB representative stated, "We have obtained patents for this strain in six countries, including Korea, Japan, China, Russia, Australia, and the United States, which has the largest market size. Through this full-scale acquisition of global rights, we can accelerate market entry and claim exclusive rights in the highly expandable therapeutic market."

This content was produced with the assistance of AI translation services.